Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2023-07-09 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - TLX 5 pages 27.3KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation (lapse) of certain securities (options, share rights, share appreciation rights) of Telix Pharmaceuticals Limited. It details the number of securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is an announcement of changes in the company's issued capital related to securities lapsing due to unmet conditions. It does not contain financial statements, audit information, or detailed financial results. It is not a full report but a regulatory announcement about securities status changes. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-07-09 English
Application for quotation of securities - TLX 7 pages 31.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and prices. This type of document is an announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2023-06-27 English
Cleansing Notice 1 page 147.5KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001, referencing the issue of fully paid ordinary shares upon exercise of unlisted share options. It is a regulatory announcement about share issuance without disclosure under part 6D.2 of the Corporations Act. The document is short (1396 characters) and serves as a formal notification rather than a detailed financial report or capital raising update. It does not contain financial statements or detailed analysis, nor is it a full capital/financing update report. This type of notice is best classified under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-06-27 English
Telix Urology Innovation Showcase 3 pages 157.8KB
Investor Presentation Classification · 95% confidence The document is an ASX release titled 'Telix Urology Innovation Showcase' dated June 21, 2023. It outlines an agenda for a shareholder briefing session including presentations by company executives and key opinion leaders. The content focuses on company strategy, product commercialization, clinical programs, and scientific insights. There are no financial statements or detailed financial data presented. The document is essentially an announcement of an upcoming investor presentation event, including registration details and webcast information. It does not contain the actual investor presentation slides or detailed financial analysis. Therefore, this document fits best as an Investor Presentation (IP) type, as it is a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation materials are not included, the agenda and content description align with this category. The document length (7686 characters) supports it being more than a brief announcement but less than a full report. Hence, the classification is Investor Presentation (IP) with high confidence.
2023-06-20 English
Lightpoint Acquisition to Expand Telix Urologic Pipeline 5 pages 219.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release announcing Telix Pharmaceuticals Limited's acquisition of Lightpoint Medical, including details of the deal terms, strategic rationale, and business integration plans. It contains no financial statements or detailed financial performance data but focuses on the transaction announcement and related conditions. The document is about a corporate acquisition and financing arrangement, including share issuance and earn-out terms. It is not an annual or interim report, earnings release, or regulatory filing of financial results. The content fits best under Capital/Financing Update (CAP) as it announces a significant acquisition and related capital structure changes (equity issuance).
2023-06-20 English
Proposed issue of securities - TLX 7 pages 33.9KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Telix Pharmaceuticals Limited regarding a proposed issue of securities, including ordinary shares and performance rights, related to an acquisition. It details the number of securities, issue dates, conditions, and compliance with ASX listing rules. The content focuses on the company's capital raising and share issuance activities rather than financial results, management changes, or legal matters. The document is lengthy (over 11,000 characters) and provides detailed information about the securities issuance, which aligns with the definition of a Capital/Financing Update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-06-20 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.